# A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments

> **NCT07881835** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 75 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT07881835
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-22
- **Primary completion:** 2029-02-16
- **Final completion:** 2029-02-16
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07881835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07881835, "A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07881835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
